Novartis Inks Chinese mRNA-Therapy Deal for Up to $7.8 Billion

Novartis AG will license a messenger RNA-based autoimmune therapy from China’s Abogen Biosciences, in a deal worth as much as $7.8 billion.

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.